These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 26796063)
61. Rational drug design of 6-substituted 4-anilino-2-phenylpyrimidines for exploration of novel ABCG2 binding site. Silbermann K; Li J; Namasivayam V; Stefan SM; Wiese M Eur J Med Chem; 2021 Feb; 212():113045. PubMed ID: 33454462 [TBL] [Abstract][Full Text] [Related]
62. Upregulation of ABCG2 via the PI3K-Akt pathway contributes to acidic microenvironment-induced cisplatin resistance in A549 and LTEP-a-2 lung cancer cells. Hu CF; Huang YY; Wang YJ; Gao FG Oncol Rep; 2016 Jul; 36(1):455-61. PubMed ID: 27221310 [TBL] [Abstract][Full Text] [Related]
64. Modulation of ABCC1 and ABCG2 proteins by ouabain in human breast cancer cells. DA Silva VA; DA Silva KA; Delou JM; DA Fonseca LM; Lopes AG; Capella MA Anticancer Res; 2014 Mar; 34(3):1441-8. PubMed ID: 24596392 [TBL] [Abstract][Full Text] [Related]
65. Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib. Zhang GN; Zhang YK; Wang YJ; Barbuti AM; Zhu XJ; Yu XY; Wen AW; Wurpel JND; Chen ZS Pharmacol Res; 2017 May; 119():89-98. PubMed ID: 28131876 [TBL] [Abstract][Full Text] [Related]
66. Superior Pyrimidine Derivatives as Selective ABCG2 Inhibitors and Broad-Spectrum ABCB1, ABCC1, and ABCG2 Antagonists. Silbermann K; Li J; Namasivayam V; Baltes F; Bendas G; Stefan SM; Wiese M J Med Chem; 2020 Sep; 63(18):10412-10432. PubMed ID: 32787102 [TBL] [Abstract][Full Text] [Related]
67. BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma. Li J; Qian C; Zhou Q; Li J; Li K; Yi P Biochem Biophys Res Commun; 2017 Sep; 491(4):939-945. PubMed ID: 28756223 [TBL] [Abstract][Full Text] [Related]
68. Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia. Huang FF; Wu DS; Zhang L; Yu YH; Yuan XY; Li WJ; Chen XP; Zhao XL; Chen FP; Zeng H Cancer Lett; 2013 Aug; 336(1):96-105. PubMed ID: 23603434 [TBL] [Abstract][Full Text] [Related]
69. Structure activity relationships, multidrug resistance reversal and selectivity of heteroarylphenyl ABCG2 inhibitors. Köhler SC; Vahdati S; Scholz MS; Wiese M Eur J Med Chem; 2018 Feb; 146():483-500. PubMed ID: 29407974 [TBL] [Abstract][Full Text] [Related]
70. CUDC-101 as a dual-target inhibitor of EGFR and HDAC enhances the anti-myeloma effects of bortezomib by regulating G2/M cell cycle arrest. Cao W; Yao S; Li A; Chen H; Zhang E; Cao L; Zhang J; Hou Y; Dai Z; Chen J; Huang X; Yang L; Cai Z J Zhejiang Univ Sci B; 2023 May; 24(5):442-454. PubMed ID: 37190893 [TBL] [Abstract][Full Text] [Related]
71. Collateral sensitivity: ABCG2-overexpressing cells are more vulnerable to oxidative stress. Krzyżanowski D; Bartosz G; Grzelak A Free Radic Biol Med; 2014 Nov; 76():47-52. PubMed ID: 25064323 [TBL] [Abstract][Full Text] [Related]
72. Targeting Corticotroph HDAC and PI3-Kinase in Cushing Disease. Zhang D; Damoiseaux R; Babayan L; Rivera-Meza EK; Yang Y; Bergsneider M; Wang MB; Yong WH; Kelly K; Heaney AP J Clin Endocrinol Metab; 2021 Jan; 106(1):e232-e246. PubMed ID: 33000123 [TBL] [Abstract][Full Text] [Related]
73. Estrogen Enhances the Expression of the Multidrug Transporter Gene ABCG2-Increasing Drug Resistance of Breast Cancer Cells through Estrogen Receptors. Chang FW; Fan HC; Liu JM; Fan TP; Jing J; Yang CL; Hsu RJ Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28098816 [TBL] [Abstract][Full Text] [Related]
74. Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. To KK; Polgar O; Huff LM; Morisaki K; Bates SE Mol Cancer Res; 2008 Jan; 6(1):151-64. PubMed ID: 18234970 [TBL] [Abstract][Full Text] [Related]
75. Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia. Li X; Su Y; Madlambayan G; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Ma J; Knight T; Wang G; Wang Y; Yang J; Taub JW; Lin H; Ge Y Haematologica; 2019 Nov; 104(11):2225-2240. PubMed ID: 30819918 [TBL] [Abstract][Full Text] [Related]
76. Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2). Spindler A; Stefan K; Wiese M J Med Chem; 2016 Jul; 59(13):6121-35. PubMed ID: 27280693 [TBL] [Abstract][Full Text] [Related]
77. Silencing of ABCG2 by MicroRNA-3163 Inhibits Multidrug Resistance in Retinoblastoma Cancer Stem Cells. Jia M; Wei Z; Liu P; Zhao X J Korean Med Sci; 2016 Jun; 31(6):836-42. PubMed ID: 27247490 [TBL] [Abstract][Full Text] [Related]
78. CC-115, a Dual Mammalian Target of Rapamycin/DNA-Dependent Protein Kinase Inhibitor in Clinical Trial, Is a Substrate of ATP-Binding Cassette G2, a Risk Factor for CC-115 Resistance. Beebe J; Zhang JT J Pharmacol Exp Ther; 2019 Nov; 371(2):320-326. PubMed ID: 31455631 [TBL] [Abstract][Full Text] [Related]
79. Vasohibin2 promotes adriamycin resistance of breast cancer cells through regulating ABCG2 via AKT signaling pathway. Ma D; Wu L; Li S; Sun Z; Wang K Mol Med Rep; 2017 Dec; 16(6):9729-9734. PubMed ID: 29039601 [TBL] [Abstract][Full Text] [Related]
80. Posttranscriptional Regulation of Human Antigen R by miR-133b Enhances Docetaxel Cytotoxicity Through the Inhibition of ATP-Binding Cassette Subfamily G Member 2 in Prostate Cancer Cells. Liu H; Song X; Hou J; Zhao Z; Chang J DNA Cell Biol; 2018 Mar; 37(3):210-219. PubMed ID: 29327946 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]